Tech Company Financing Transactions

BioEclipse Therapeutics Funding Round

Revelis Capital, DEFTA Partners and Foothill Ventures participated in a $7.7 million Series A funding round for BioEclipse Therapeutics. The round was announced on 6/25/2019.

Transaction Overview

Announced On
6/25/2019
Transaction Type
Venture Equity
Amount
$7,700,000
Round
Series A
Proceeds Purpose
BioEclipse plans to use proceeds from the Series A-1 financing to initiate human trials of CRX-100, BioEclipse's patented, first-in-class, intravenous, tumor targeted combination immunotherapy.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Blvd. 3rd Floor S.
San Francisco, CA 94080
USA
Email Address
Overview
BioEclipse Therapeutics is an emerging, clinical-stage biopharmaceutical company committed to delivering first-in-class, curative immune-oncology therapeutics to patients with cancer. Our focus is on currently untreatable cancers where our unique approach may be able to address needs of patients with cancers that most think not possible.
Profile
BioEclipse Therapeutics LinkedIn Company Profile
Social Media
BioEclipse Therapeutics Company Twitter Account
Company News
BioEclipse Therapeutics News
Facebook
BioEclipse Therapeutics on Facebook
YouTube
BioEclipse Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Catherine Sohn
  Catherine Sohn LinkedIn Profile  Catherine Sohn Twitter Account  Catherine Sohn News  Catherine Sohn on Facebook
Chief Executive Officer
Pamela Contag
  Pamela Contag LinkedIn Profile  Pamela Contag Twitter Account  Pamela Contag News  Pamela Contag on Facebook
Chief Financial Officer
Benjamin Carter
  Benjamin Carter LinkedIn Profile  Benjamin Carter Twitter Account  Benjamin Carter News  Benjamin Carter on Facebook
Co-Founder
Christopher Contag
  Christopher Contag LinkedIn Profile  Christopher Contag Twitter Account  Christopher Contag News  Christopher Contag on Facebook
Co-Founder
Robert Negrin
  Robert Negrin LinkedIn Profile  Robert Negrin Twitter Account  Robert Negrin News  Robert Negrin on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/25/2019: Alma venture capital transaction
Next: 6/25/2019: Corinth MedTech venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary